BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24083738)

  • 1. Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors?
    Demir L; Ekinci N; Erten C; Kucukzeybek Y; Alacacioglu A; Somali I; Can A; Dirican A; Bayoglu V; Akyol M; Cakalagaoglu F; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(8):4751-8. PubMed ID: 24083738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
    BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
    Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
    Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors.
    Wang H; Chen P; Liu XX; Zhao W; Shi L; Gu XW; Zhu CR; Zhu HH; Zong L
    World J Surg Oncol; 2014 Apr; 12():89. PubMed ID: 24712384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 labeling index may be a promising indicator to identify "very high-risk" gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients.
    Liu X; Qiu H; Zhang P; Feng X; Chen T; Li Y; Tao K; Li G; Sun X; Zhou Z;
    Hum Pathol; 2018 Apr; 74():17-24. PubMed ID: 28962945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors.
    Liang YM; Li XH; Li WM; Lu YY
    World J Gastroenterol; 2012 Apr; 18(14):1664-71. PubMed ID: 22529697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors.
    Wang Y; Chen JJ; Wang XF; Wang Q
    World J Gastroenterol; 2018 Jun; 24(23):2508-2517. PubMed ID: 29930472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of prognostic factors for patients with gastrointestinal stromal tumors].
    Jie ZG; Xie XP; Qin KW; Liu Y; Li ZR; Dai AB; Yao YX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2005 May; 8(3):210-2. PubMed ID: 16167229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification in GIST: shape quantification with CT is a predictive factor.
    Wei SC; Xu L; Li WH; Li Y; Guo SF; Sun XR; Li WW
    Eur Radiol; 2020 Apr; 30(4):1856-1865. PubMed ID: 31900704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.
    Song Z; Wang JL; Pan YL; Tao DY; Gan MF; Huang KE
    Hepatogastroenterology; 2009; 56(89):149-53. PubMed ID: 19453047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors.
    Tai WC; Chuah SK; Lin JW; Chen HH; Huang HY; Kuo CM; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Nov; 20(5):1157-64. PubMed ID: 18949416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis analysis of 247 cases of gastrointestinal stromal tumor].
    Ning L; Zhang DF; Zhou YB; Jiao XL; Cao SG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):247-50. PubMed ID: 23536345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein S100 as prognostic marker for gastrointestinal stromal tumors: a clinicopathological risk factor analysis.
    Perez D; Demartines N; Meier K; Clavien PA; Jungbluth A; Jaeger D
    J Invest Surg; 2007; 20(3):181-6. PubMed ID: 17613693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinicopathologic and immunohistochemical study on 76 cases of gastrointestinal stromal tumors].
    Hou Y; Wang J; Zhu X; Du X; Sun M; Zheng A
    Zhonghua Bing Li Xue Za Zhi; 2002 Feb; 31(1):20-5. PubMed ID: 11955330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
    Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) as a prognostic indicator in primary gastrointestinal stromal tumors.
    Xie W; Xiao H; Luo J; Zhao L; Jin F; Ma J; Li J; Xiong K; Chen C; Wang G
    Curr Probl Cancer; 2020 Dec; 44(6):100593. PubMed ID: 32507364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.